| Literature DB >> 12848968 |
Abstract
Liver transplantation is now the accepted treatment for patients with end-stage disease or intractable symptoms. The success rate is high. Those grafted for PBC are at greater risk of developing acute and chronic rejection and are less likely to be weaned from immunosuppression. Following transplantation, AMA persist and histological features of PBC may be seen in the allograft, in up to 50% by 10 years.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12848968 DOI: 10.1016/s1568-9972(02)00103-9
Source DB: PubMed Journal: Autoimmun Rev ISSN: 1568-9972 Impact factor: 9.754